The correction of anemia currently relies on use of intravenous erythropoiesis‐stimulating agents and iron administration, however, recombinant human EPO and its analogues have been associated with increased risk of adverse cardiovascular events.2, 3. Here, EPO is linked to anemia (phenotype).